Picoplatin
| Code | Size | Price |
|---|
| TAR-T21323-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Picoplatin has a broad spectrum of antineoplastic activity and is designed to overcome platinum drug resistance. Picoplatin alkylates DNA, forming both intra- and inter-strand cross-linkages, resulting in the inhibition of DNA replication and transcription, and the induction of apoptosis.
CAS:
181630-15-9
Formula:
C6H10Cl2N2Pt
Molecular Weight:
376.14
Purity:
0.98
SMILES:
N.Cl[Pt]Cl.Cc1ccccn1
References
1. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091.
2. Margiotta N, Denora N, Ostuni R, Laquintana V, Anderson A, Johnson SW, Trapani G, Natile G. Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein. J Med Chem. 2010 Jul 22;53(14):5144-54. PubMed PMID: 20568783.
3. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, Giacomini KM. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010 Apr;9(4):1058-69. Epub 2010 Apr 6. PubMed PMID: 20371711.
4. Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010 May 1;10(4):293-301. Review. PubMed PMID: 20187870.